Search Patents
  • Radiohalogenated half-antibodies and maleimide intermediate therefor
    Patent number: 4994557
    Abstract: N-(m-radiohalophenyl) maleimide can be conjugated with a reduced antibody having a mercapto group to provide a radiolabelled half-antibody having immunological specific binding characteristics of whole antibody.
    Type: Grant
    Filed: January 29, 1988
    Date of Patent: February 19, 1991
    Assignee: President and Fellows of Harvard College
    Inventors: Amin I. Kassis, Leslie A. Khawli
  • METHODS AND COMPOSITIONS FOR RADIOHALOGEN PROTEIN LABELING
    Publication number: 20160002121
    Abstract: Methods and compositions are provided for labeling proteins with radiohalogen-label reagents. Radiohalogen-labeled proteins may be used for imaging studies, as therapeutics and in diagnostic tests. The [125I] HIP-DOTA label reagent 6 is prepared by an efficient and convenient process.
    Type: Application
    Filed: July 31, 2015
    Publication date: January 7, 2016
    Applicant: GENENTECH, INC.
    Inventors: Charles Andrew Boswell, Leslie A. Khawli, Jan Marik, Simon Williams
  • M-aminophenyltrialkylstannane
    Patent number: 4977288
    Abstract: m-Radiohalo-aniline is a stable intermediate for preparing biotin-m-radiohalo-anilide to be used as an imaging agent or therapeutic agent. The invention also contemplates m-aminophenyltrialkylstannane which can be radiohalogenated and linked to biotin.
    Type: Grant
    Filed: January 29, 1988
    Date of Patent: December 11, 1990
    Assignee: President and Fellows of Harvard College
    Inventors: Amin I. Kassis, Leslie A. Khawli
  • CpG IMMUNOCONJUGATES FOR CANCER THERAPY
    Publication number: 20230331849
    Abstract: Applicant discloses herein an immunoconjugate, which enables systemic use of targeted CpG using a new class of antibodies which target the tumor microenvironment. Conjugation to checkpoint inhibitors such as anti-PD-L1, anti-CTLA-4, anti-LAGS anti-TIM-3, and anti-VISTA to make “biobetter” reagents.
    Type: Application
    Filed: September 8, 2021
    Publication date: October 19, 2023
    Inventors: Alan Epstein, Peisheng Hu, Leslie Khawli
  • Methods and compositions for radiohalogen protein labeling
    Patent number: 9486546
    Abstract: Methods and compositions are provided for labeling proteins with radiohalogen-label reagents. Radiohalogen-labeled proteins may be used for imaging studies, as therapeutics and in diagnostic tests. The [125I] HIP-DOTA label reagent 6 is prepared by an efficient and convenient process.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: November 8, 2016
    Assignee: GENENTECH, INC.
    Inventors: Charles Andrew Boswell, Leslie A. Khawli, Jan Marik, Simon Williams
  • Targeted innate immunity
    Publication number: 20060135459
    Abstract: Provided is a cancer therapeutic agent comprising a cancer targeting molecule linked to a CpG oligodeoxynucleotide. Also provided are methods of reducing the size of a tumor or inhibiting the growth of cancer cells in an individual or inhibiting the development of metastatic cancer, comprising administering an effective amount of the cancer therapeutic agent. The methods may also include reducing immunoregulatory T cell activity in the individual.
    Type: Application
    Filed: November 8, 2005
    Publication date: June 22, 2006
    Inventors: Alan Epstein, Leslie Khawli
  • Cancer targeted innate immunity
    Patent number: 9522958
    Abstract: Provided is a cancer therapeutic agent comprising a cancer targeting molecule linked to a CpG oligodeoxynucleotide. Also provided are methods of reducing the size of a tumor or inhibiting the growth of cancer cells in an individual or inhibiting the development of metastatic cancer, comprising administering an effective amount of the cancer therapeutic agent. The methods may also include reducing immunoregulatory T cell activity in the individual.
    Type: Grant
    Filed: September 8, 2011
    Date of Patent: December 20, 2016
    Assignee: University of Southern California
    Inventors: Alan L. Epstein, Leslie A. Khawli
  • Methods and compositions for radiohalogen protein labeling
    Patent number: 9393327
    Abstract: Methods and compositions are provided for labeling proteins with radiohalogen-label reagents. Radiohalogen-labeled proteins may be used for imaging studies, as therapeutics and in diagnostic tests. The [125I] HIP-DOTA label reagent 6 is prepared by an efficient and convenient process.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: July 19, 2016
    Assignee: GENENTECH, INC.
    Inventors: Charles Andrew Boswell, Leslie A Khawli, Jan Marik, Simon Williams
  • METHODS AND COMPOSITIONS FOR RADIOHALOGEN PROTEIN LABELING
    Publication number: 20140170064
    Abstract: Methods and compositions are provided for labeling proteins with radiohalogen-label reagents. Radiohalogen-labeled proteins may be used for imaging studies, as therapeutics and in diagnostic tests. The [125I] HIP-DOTA label reagent 6 is prepared by an efficient and convenient process.
    Type: Application
    Filed: December 18, 2013
    Publication date: June 19, 2014
    Applicant: Genentech, Inc.
    Inventors: Charles Andrew Boswell, Leslie A. Khawli, Jan Marik, Simon Williams
  • CANCER TARGETED INNATE IMMUNITY
    Publication number: 20120076804
    Abstract: Provided is a cancer therapeutic agent comprising a cancer targeting molecule linked to a CpG oligodeoxynucleotide. Also provided are methods of reducing the size of a tumor or inhibiting the growth of cancer cells in an individual or inhibiting the development of metastatic cancer, comprising administering an effective amount of the cancer therapeutic agent. The methods may also include reducing immunoregulatory T cell activity in the individual.
    Type: Application
    Filed: September 8, 2011
    Publication date: March 29, 2012
    Inventors: Alan L. Epstein, Leslie A. Khawli
  • Polymer-bound antibody cancer therapeutic agent
    Publication number: 20050214286
    Abstract: Described is a cancer therapeutic agent comprising a polymer to which is linked three or more anti-tumor cell antibodies. Soluble polymers of between 6-8 Kd in size are preferred. The antibodies of the polymer can bind to a tumor cell antigen of a tumor cell and induce apoptosis or cell death of the tumor cell. The polymer may be linked to different antibodies to the same tumor antigen or to different tumor antigens. Methods of treating an individual with cancer using the cancer therapeutic agent are also described.
    Type: Application
    Filed: January 27, 2005
    Publication date: September 29, 2005
    Inventors: Alan Epstein, Leslie Khawli
  • Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof
    Publication number: 20040156824
    Abstract: A novel permeability enhancing peptide (PEP) is a fragment of interleukin-2. When joined to a delivery vehicle that can target a tumor site, the PEP can increase the subsequent uptake of antineoplastic or tumor imaging agents. The PEP can be chemically joined to a monoclonal antibody to form an immunoconjugate. Alternatively, an expression vector is genetically engineered to express a fusion protein. The fusion protein has an antigen-binding portion joined to the PEP. The PEP is most effective when it takes the form of a dimer, linked by a disulfide bridge. The PEP is substantially free of cytokine activity and produces minimal toxic side effects on normal tissues.
    Type: Application
    Filed: February 27, 2004
    Publication date: August 12, 2004
    Inventors: Alan L. Epstein, Leslie A. Khawli
  • Modified antibodies
    Patent number: 5194594
    Abstract: Modified antibodies are disclosed which have been modified by chemical conjugation with a heterobifunctional reagent, such as SPDP. The use of these modified antibodies in the diagnosis and therapy of cancer and other mammalian disease is also disclosed. Diagnostic uses include immunoscintography. The modified antibodies may be further conjugated with labels or biologically active molecules for use in such diagnosis and therapy. The modified antibodies may also be formulated into pharmaceutical compositions for these purposes.
    Type: Grant
    Filed: September 7, 1990
    Date of Patent: March 16, 1993
    Assignee: Techniclone, Inc.
    Inventors: Leslie A. Khawli, Alan L. Epstein
  • Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof
    Publication number: 20020164302
    Abstract: A novel permeability enhancing peptide (PEP) is a fragment of interleukin-2. When joined to a delivery vehicle that can target a tumor site, the PEP can increase the subsequent uptake of antineoplastic or tumor imaging agents. The PEP can be chemically joined to a monoclonal antibody to form an immunoconjugate. Alternatively, an expression vector is genetically engineered to express a fusion protein. The fusion protein has an antigen-binding portion joined to the PEP. The PEP is most effective when it takes the form of a dimer, linked by a disulfide bridge. The PEP is substantially free of cytokine activity and produces minimal toxic side effects on normal tissues.
    Type: Application
    Filed: May 9, 2002
    Publication date: November 7, 2002
    Inventors: Alan L. Epstein, Leslie A. Khawli
  • Antibodies with reduced net positive charge
    Patent number: 5990286
    Abstract: Modified antibodies which have been by chemical conjugation with agents reactive with free amino groups are disclosed. Among the chemical agents disclosed for use in connection with the invention are heterobifunctional reagents and biotin. The use of these modified antibodies in the diagnosis and therapy of cancer and other mammalian disease is also disclosed. Diagnostic uses include immunoscintography. The modified antibodies may be further conjugated with labels or biologically active molecules for use in diagnosis and therapy. The modified antibodies may also be formulated into pharmaceutical compositions for these purposes.
    Type: Grant
    Filed: January 10, 1997
    Date of Patent: November 23, 1999
    Assignee: Techniclone, Inc.
    Inventors: Leslie A. Khawli, Alan L. Epstein
  • Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof
    Patent number: 6403096
    Abstract: A novel permeability enhancing peptide (PEP) is a fragment of interleukin-2. When joined to a delivery vehicle that can target a tumor site, the PEP can increase the subsequent uptake of antineoplastic or tumor imaging agents. The PEP can be chemically joined to a monoclonal antibody to form an immunoconjugate. Alternatively, an expression vector is genetically engineered to express a fusion protein. The fusion protein has an antigen-binding portion joined to the PEP. The PEP is most effective when it takes the form of a dimer, linked by a disulfide bridge. The PEP is substantially free of cytokine activity and produces minimal toxic side effects on normal tissues.
    Type: Grant
    Filed: November 18, 1999
    Date of Patent: June 11, 2002
    Assignee: University of Southern California
    Inventors: Alan L. Epstein, Leslie A. Khawli
  • Method for the diagnosis of neoplastic tissue comprising administering a vasopermeability enhancing peptide of human interleukin-2
    Patent number: 6737064
    Abstract: A novel permeability enhancing peptide (PEP) is a fragment of interleukin-2. When joined to a delivery vehicle that can target a tumor site, the PEP can increase the subsequent uptake of antineoplastic or tumor imaging agents. The PEP can be chemically joined to a monoclonal antibody to form an immunoconjugate. Alternatively, an expression vector is genetically engineered to express a fusion protein. The fusion protein has an antigen-binding portion joined to the PEP. The PEP is most effective when it takes the form of a dimer, linked by a disulfide bridge. The PEP is substantially free of cytokine activity and produces minimal toxic side effects on normal tissues.
    Type: Grant
    Filed: May 9, 2002
    Date of Patent: May 18, 2004
    Assignee: The University of Southern California
    Inventors: Alan L. Epstein, Leslie A. Khawli
  • Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof
    Patent number: 6008319
    Abstract: A novel permeability enhancing peptide (PEP) is a fragment of interleukin-2. When joined to a delivery vehicle that can target a tumor site, the PEP can increase the subsequent uptake of antineoplastic or tumor imaging agents. The PEP can be chemically joined to a monoclonal antibody to form an immunoconjugate. Alternatively, an expression vector is genetically engineered to express a fusion protein. The fusion protein has an antigen-binding portion joined to the PEP. The PEP is most effective when it takes the form of a dimer, linked by a disulfide bridge. The PEP is substantially free of cytokine activity and produces minimal toxic side effects on normal tissues.
    Type: Grant
    Filed: December 23, 1996
    Date of Patent: December 28, 1999
    Assignee: University of Southern California
    Inventors: Alan L. Epstein, Leslie A. Khawli
Narrow Results

Filter by US Classification